1. Exemestane is a steroidal Aromatase Inhibitor (AI) that is most commonly known as Aromasin. In fact, the Aromasin brand name is the only pharmaceutical grade brand of the Exemestane AI due to the tight patent Upjohn has maintained on the product. While tightly controlled by the pharmaceutical giant, Aromasin is available in numerous countries around the globe.
2. Aromasin was first released on the U.S. market in 2000 after shortly gaining FDA approval a few months prior in 1999. The primary purpose of use as with most AI's would be to combat breast cancer in post-menopausal women. Shortly after, the AI would begin to gain a lot of popularity among anabolic steroid users for its ability to protect against estrogenic related side effects. This action is very similar to the older and more popular AI's in Arimidex and Femara It would also gain a fair amount of popularity in Post Cycle Therapy (PCT) plans among steroid users. It was not the first AI to gain such popularity but would prove to be a little more advantageous for this purpose than most AI's.
China
